Τόμος 5 (1987) – Τεύχος 4 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 5 (1987) – Issue 4 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ιωάννης Ε. Αναστασόπουλος

Νευρολογική Κλινική Νοσοκομείου “Παμμακάριστος”, Αθήνα

I.E. Anastasopoulos

Neurological Clinic of “Pammakaristos” Hospital, Athens, Greece

1. Firth, D.: The case of Augustus D’Este. Cambridge uni¬versity Press, 1948
2. M~ttyus, A. and Veres, Ε.: M.S. in childhood: long term katamnestic investigation. Acre Peed, Hung. 26: 193 (1985)
3. Noseworthy, J., Paiy, D., Wonnacott, T., Feasby, T., Ebers, G.: Μ.S after age 50. Neurology (N.Y.) 33.’ 1537 (1983)
4. Hammann, K.P. and Hopf, H.C.: Monocytes constitute the only peripheral blood cell ρορulatiοn showing an increa¬sed burst activity in M.S patients. Intern. Arch. Allergy and App!. immuiwi. (Switz.) 81: 230 (1986)
5. Hauser, S.L.: CSF cells in M.S. Neurology 33: 575 (1983)
6. Naess, Α.: Τ lymphocytes in C.S.F. from patients with neurological disease. Europ. Neurol. 18: 183 (1979)
7. Oger, J-, Antel, J.P., Noronha, Α. and Arnason, B.G-W.: Changes in Τ cell subpopulations in the CSF of Μ.S. patients. Neurology 32: 1484 (1982)
8. SchdJich, H.-J., Bliersbech, Y., Felgenhauer, Κ. and Schifferdecker, Μ.: ΟΚΤ-8 binding lymphocytes in disea¬ses of the nervous system. J. Neuroimmunol. 5: 289 (1983)
9. Cashman, N., Martin, C., -Eizenbaum, J.-F. and Degos, J.-D.: Monoclonal antibody-defined immunoregulatory cells in M.S. CSF. J. Clin. Invest. 70: 387 (1982)
10. Kolar, Ο.J., Rice, P.H., Bauer, D.C., Defalque, R.J., Danielson, C.F., Farlow, Μ.R. and Wright, J.H.: Clinical implications of studies involving CSF Τ cell subpopula¬lions. In G. Scarluto απd W.B. Matthews (eds), M.S.: Presnt and Future. New York, Plenum Press, 20311984)
11. Sears, E.S., Tindall, R.S.A. απd Zarnow, Η.: Active MS.: enhanced computerized tomographic imaging lesions and the effect of corticosteroids. Arch. Neurol. 35: 426 (1978)
12. Aita, J.F., Bennett, D.D., Anderson, R.E. and Ziter, F.: Cranial CT appearance of acute M.S. Neurology 28: 251 (1978)
13. Lebow, S., Anderson, D.C., Mastri, A. and Larson, D.: Acute M.S. with contrast-enhancing plaques. Arch. Neurol. 35: 435 (1978)
14. Tourtellote, W.W. and Ma, B.I.: M.S.: The blood brain bar¬rier and the measurement of de-nova CNS IgG synthesis. Neurology 28: 76 (1978)
15. Tourtellotte, W.W., Walsh, M.J., Baumhefner, R.W., Staugaitis, S.M., Shapshak, P.: The current status of M.S. intro blood-brain-barrier IgG synthesis. Ann. N.Y. Aced. Sci. 436: 52 ( 1984)
16. Withrich, R.: CT scanning in demyelineting disease. In:
    L aubsch and Razner (eds), Cranial Computerized Tomo¬graphy, Springer-Verlag. 239 (1976)
17. Cola, L.A., Mastaglia, F,L. and Black, J.L.: Computerized tomography of brain and optic nerve in M.S. J. Neurol.
    S ci. 36: 411 (1978)
18. Kurtzke, J.F.: On the fine structure of the distribution of M.S. Acts Neurol. Scand. 43: 257 (1967)
19. Kurtzke, J.F.: Further features of the Fennoscandian fo¬cus of M.S. Ada Neurol- Scand. 50: 478 (1974)
20. Larsen, J.P., Aerli, J.A., Nyland. Η. and Riise, T.: West Norway – a high-risk area for M.S. Neurol 34: 1202 (1984)
21. Shepherd, D.I. and Downie, A.W.: Prevalence of M.S. in northeast Scotland. 8r. Med. J. 2: 314 (1978)
22. Poskenzer, D.C., Prenriey, L.Θ., Sheridan, J.L. απd Von¬kondy, J.: M.S. in the Orkney απd Shetland Islands. J. Epidemiol. Common. Health 34: 229 (1980)
23. Τσσκανίκας, Κ.: Enιδημιoλογiα και Γενετική της ΣKΠ. Εyκέ¬φαλος 18: 337 (1981)
24. Vassilopoulos, D.: Epidemiological data for M.S. in Gree¬ce. Neuroepidemiology 3: 52 (1985)
25. Ραακoνίκας, Κ., Κuλιντηρkας, Κ., Παnαγκωργiου, K.O.: Πρόδρομcς ιαροτηρήαεις via τη ouχνότητα, τa 06/o και την ηλικία των ασθενών με ΣΚΓ1 στην Ελλάδα. Materia Medics Greco 13: 440 (1985)
26. Poser, C.M.: Σκλήρuvσις κατά πλάκας: Μια κριτική Ενημέ¬ρωaις δια τa σημερινά δεδομένα. Medical Clinics of North America. Clinical Neurology 4: 993 (1979)
27. Kurtzke, J.F., Gudmundsson, K.R. and Bergmann, S.: M.S. in Iceland. I. Evidence of a postwar epidemic. Neuro¬logy 32.• 143 (1982)
28. Kurtzke, J.F. and Hyl[ested, Κ.: M.S in the Faroe Islands II. Clinical update, transmission and nature of M.S. Neuro¬logy 36: 307 (1986)
29. Dean, G. and Kurtzke, J.F.: On the risk of M.S. according to age at immigration to South Africa. British Med. J. 3: 721 (1971)
30. Alter, M., Kahaiia, Ε. and Loewenson, R.: Migration απd risk of M.S. Neurology 28: 1089 (1978)
31. Sullivan, C.Θ., Visscher, S.R., Detels, R.: M.S. and age at exposure to childhood disease and animals – cases απd their friends. Neurology 34: 1144 (1984)
32. Fischman, HR.: M.S. A two-stage process? Am. J. Epi¬demiol. 114: 244 (1981)
33. Waksman, B.H. and Reynolds, W.Σ.: M.S. as a disease of immune regulation. Proc. Soc. Exp. 8101. Med. 175: 282 (1984)
34. Lavi, Ε.: The viral hypothesis of the etiology of M.S. Hare¬fuah (Hebrew) 109: 197 (1985)
35. Sibley, W.A., Bamford, C.R., Clark, Κ.: Clinical viral infe¬ctions απd M.S. Lancet 1: 1313 (1985)
36. Lamer, A.J.: Aetiological role of viruses in M.S. (a review). J. R. Soc. Med. 79: 412 (1986)
37. McDonald, W.I.: The mystery of the origin of M.S.J. Neu¬rol Neurosurg. Psy. 49: 113 (1986)
38. Weiner, H.L., Hailer, D.A.: Multiple sclerosis. In: Appel S.H. (ed.), Current Neurology, Chicago, Year Book, 123 (1986)
39. Adams, J.M. and Imagawa, D.T.: Measles antibodies in M.S. Proc. Soc. Exp. 8i01. Med. 111: 562 (1962)
40. Schapiro, K., Poskanzer, D.C. and Miller, Η.: Familial and conjugal M.S. Brain 86: 315 (1963)
41. Mac Kay, R.P. and Myrianthopoulos, N.C.: M.S. in twins and their relatives. Final report. Arch. of Neurol 15: 449 (1966)
42. Bobowick, A.R., Kurtzke, J.F., Brody, J.Α., Hrubec, Ζ. απd Gillespie, Μ.: Twin study of M.S. – an epidemiologic in¬quiry. Neurology 28: 978 (1978)
43. Hettberg, Α. and Holm, N.V.: Concordance in twins and recurrence in sibships in M.S. Lancet 1: 1062 (1982)
44. McFarland, H.F., Greenstein, J., McFarlin, Ω.Ε., Eldridge, R., Xu, X.H., Krebs, Η.: Family απd twin studies in M.S. Ann. N.Y. Aced. Sci. 436: 118 (1984)
45. Detels, R., Visscher, B.R., Malmgren, R.M., Coulson, AK., Lucia, M.V. and Dudley, J.P.: Evidence for lower susce¬ptibility to M.S. in Japanese Americans. Am. J. Epide¬miol. 105: 303 (1977)
46. Detels, R., Brody, J.A. and Edgar, A.H.: M.S. among American, Japanese and Chinese migrants to California and Washington. J. Chronic Dis. 25: 3 (1972)
47. Madigand, M.. Oger, J., Fauchet, R., Sabouraud, 0.: HLA profiles in MS suggest two forms of disease and the existence of protective haplotypes. J. Neurol, Sci. 53:519 (1982)
48. Duquette, P., Ddcary, F., Pleines, J., Boivin, D., Lamou¬reux, G., Gosgrove. J.B., Lapierre, Υ.: Clinical sub-groups
    of MS in reΓatiοn to ΗLΑ. DR alleles as possible markers et disease progression. Can. J. Neurol. Sci. 12: 106 (1985)
49. Dausset, J.: The major histocompatibility complex in man. Science 213: 1469 (1981)
50. Van Voorhis, W.C., Witmer, M.D. and Steinman, R.M.: The phenotype of dendritic cells and macrophages. Fed. Proc. 42: 3114 (1983)
51. Paterson, P.Y., Day, Ε.D., Whitacre, C.C., Berenberg, R.A. and Harter. D.H.: Endogenous MBP serum factors and anti-MBP antibodies in humans. J. Neurol. Sc! 52: 37 (1981)
52. Hafler, D.Α., Benjamin, D.S., Burks, J., Weiner, H.L.: MBP and proteolipid protein reactivity of brain – and CSF – derived Τ cell clones in MS and postinfectious encephalo¬myelitis. J. immune!. 139.- 68 (1987)
53. Nubile, O.E., Spagnol, G., Daverio, R., Riboni, L, Macchi, R., Frencomano, E., Scarlato, G.: Studies on anti-myelin antibodies in patients with MS. Ply. Neurol. 57: 13 (1987)
54. Huddlestone, J.R. and Oldstońe, M.B.A.: T suppressor lymphocytes fluctuate in parallel with changes in the clinical course of patients with MS. J. Immune!. 123: 1615 (1978)
55. Bach, Μ.Α., Phan-Dinh-Tuy, F., Tournier, E., Chatenoud,
    L. and Bach, J.-F.: Deficit of suppressor Τ cells in active MS. Lancet 2: 1221 (1980)
56. Reinherz, E.L., Weiner, H.L., Hauser, S.L., Cohen, J.Α., Distaso, J.A. and Schlossman, S.F.: Loss of suppressor Τ cells in active MS: analysis with monoclonal antibodies. N. Eπgl. J. Med. 303: 125 (1980)
57. Huddlestone, J.R. and Oldstone, M.B.A.: Suppressor Τ cells are activated in vivo in patients with MS coinciding with remission from acute attack. J. immunoL 129: 915 (1982)
58. Paty, D.W. and Kastrukοff, L.F.: Suppressor Tcells in MS: Do changes in numbers vary with clinical activity? Any. N.Υ. Aced, Sc! 436: 266 (1984)
59. Merrill, J.E., Mohlstrom, C., Vittenhogaart, C.. Kermania¬rab, V., Ellison, G.W. and Myers, L.W.: Response to and production of interleukin 2 by peripheral blood and CSF lymphocytes of patients with MS. J. immune!. 133: 1931 ( 1984)
60. De Freitas, E.C., Sandberg-Wollheim, M., Schonely, Κ., Boufal, M., Koprowski, H.: Regulation of interleukin-2 receptors on Τ cells from MS patients. Proc. Nat!. Aced. Sc! (USA) 83: 2637 (1986)
61. Verselis, S.L. and Gοust, J.M.: CD4 + T cell activation in MS. J Neuroimmunol. 14: 75 (1987)
62. Steinman, L., Schwartz, G., Welder, M., O’Hearn, Μ., Lim Μ. and Sriram, S.: Gene specific and antigen specific strategies for the induction of suppressor Τ cells to mye¬lin basic protein. In: E.C. Alvord Jr., Μ.W. Kies and A.J. Suckling (eds), Experimental Allergic Encephalomyelitis: A Useful Model for MS. New York, Alan R. Liss, Inc., 393 (1984) .
63. Traugott, U.: MS: relevance of class I and class II MHC expressing cells to lesion development. J. Neuroimmu¬nol. 16: 283 (1987)
64.  Santoli, D., Hall, N., Kastrukoff, L., Lisak, R.P., Perussia, B., Trinchieri, G. and Koprowski, Η.: Cytotoxic activity and interferon production by lymphocytes from patients with MS. J. immune!. 126.• 1274 (1981)
65. Neighbour, RA., Graynel, A.I. and Miller, Α.E.: Endogenous and interferon-augmented natural killer cell activity Of human peripheral blood mononuclear cells in vitro. Studies of patients with MS, lupus and rheumatoid ar¬thritis. Clin. Exp. immune!. 49: 11 (1982)
66. Ortaldo, J.R., Mantovani, A., Hobbs, D., Rubinstein, Μ., Pestka, S. and Herbermann, R.B.: Effete Of several spe¬cies of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. int. J. Cancer 31: 285 (1983)
67. Vervliet, G., Carton, H., Meulepas, E., Billiau, A.: Interferon production by cultured peripheral lymphocytes of MS patients. Clin. όxρ. immune!. 58: 116 (1984)
68. Rager-Zisman, 8. and Bloom, B.R.: Natural killer cells in resistance to virus infected cells. Springer Sem. lmmu¬nopathol. 4.• 397 (1980)
69. Hauser, S.L., Ault, K.A., Levin, M.J., Garovoy, M.R. and Weiner, H.L.: Natural killer cell activity in MS. J. immu¬no!. 127: 1114 (1981)
70. Merrill, J.E., Jondal, M., Seeley, J., Ullberg, M. and Siden, A.: Decresed NK killing in patients with MS. Clin. Exp. immune!. 47.• 419 (1982)
71.  Benczur, M., Petr~nyi, G., Palffy, Gy., Varga, Μ., Tales, M., Kotsy, B., Foldes, I. and Holden, S.R.: Dysfunction of natural killer cells in MS: a possible pathogenetic factor. Clin. Exp. immune!. 39: 657 (1980)
72. Neighbour, P.A. and Bloom, B.R.: Absence of virus indu¬ced lymphocyte suppresson and interferon production in MS. Proc. Nation. Aced. Sc!. (USA) 76: 476 (1979)
73. Neighbour, P.A., Miller, Α.E. and Bloom, Θ.R.: Interferon responses of leucocytes in MS. Neurology 3/.561(1981)
74. Neighbour, P.Α.: Studies of interferon production and natural killing by lymphocytes from MS patients. Ann. N.Y. Aced, Sc! 436: 181 (1984) (41 ref.)
75. Kamin-Lewis, R.M., Panitch, H.S., Merigan, T.C., John¬son. Κ.A.: Decreased interferon synthesis and responsi¬veness to interferon by Leukocytes from MS patients given natural alpha interferon. J. lnfeferon Res. 4: 423 ( 1984)
76. Kamin-lewis, R.M., Panitch, H.S., Johnson, Κ.Ρ.: Pa¬tients respond to alpha and gamma interferons. J. Neuro¬immune!. 9: 221 (1985)
77. Besedovsky, H.O., Del Rey, A.E. and Sorkin, Ε.: What do the immune system and the brain know about each other? immune!. Today 4: 342 (1983)
78. Mertin, J.: MS and Immunity: Facts, Fiction and Future development in MS research in Europe. Hommes D.R. (ed.), ΜΤΡ Press. For the Commission of the European .Communities, 103 (1985)
79. Σύγχρονη Oερaπεuτική Conn H.F., Saunders, Co. Σκλήρυνση κατά πλάκας 3.. 1185 (1983-84)
80. Sharpe, R.J.: The low incidence of MS and areas near the equador may be due to ultraviolet light induced suppres¬sor cells to melanocyte antigens. Med. Hypothesis 19: 319 (1986)
81. Feldman, R.G.. Kelly-Hayes, M., Conomy, J.P., Foley, J.M.: Baclofen for spasticity in MS. Double blind crosso¬ver and three year study. Neurology 28.’ 1094 (1978)
82. Rudick, R.A., Breton, D., Kroll, R.L.: The GAGA-agonist progabide for spasticity in MS. Arch. Neural. 44: 1033 (1987)
83. Sabra, A,F., Hallet, Μ., Sudarsky, L and Mullally, Μ.: Treatment of action tremor in MS with isoniazid. Neuro¬logy 32: 912 (1982)
84. Duquette, P., Pleines, J., Du Souich, Ρ.: Isoniazid for tremor in MS, a controlled trial. Neurology 35: 1772 (1985)
85. Mertin, J.: Drug treatment of patients with MS. In: Hand¬book of Clinical Neurology by Vinken and Bruyn. J.C. Koetsier (ed.), Elsevier Science Publishers B.V., Vol. 3 (47): 187 (1985)
86. Brown, J.R., Beebe, G.W., Kurtzke, J.F., Loewenson, R.B., Silbergerg, D.H. and Tourtelotte, W.W.: The design of cli¬nical studies to assess therapeutic efficacy in MS. Neuro¬logy 29: 3 (1979)
87. Kurtzke, J.: Rating neurologic impairment in MS: An expanded disability status scale. SDSS Neurology 33.• 1444 (1963)
88. Poser, C.M., Paty, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.S., Johnson, K.P., Sibley, W.A., Sil¬berg, D.N. and Tourtellotte, W.W.: New diagnostic criteria for MS-guideines for research protocols. Ann. Neural. 13: 227 (1983)
89. Compston, A,: Selection of patients for clinical trials. Neuroepidemiology 6 (7-2): 34 (1987)
90. Hommes, O.R., Lamers, K.J.B. and Reekers, P.: Prognostic factors in intensive immunosuppresive treatment of chronic progresive MS. In: H. Bauer, S. Poser and G. Rit¬ter (eds), Progress in MS Research. Berlin – Heidelberg – New York, Springer Verlag, 396 (1980)
91. Campeil, B., Vogel, P.J., Fisher, Ε. απd Lorenz, R.: Myelin basic protein administration in MS. Arch. Neurol. 29: 10 ( 1973)
92. Gonsette,R.E., Delmotte, P. and Demonty, L: Failure of basic protein therapy for MS. J. NeuroL 216: 27 (1977)
93. Romine, J.S. απd Salk, J.: A study of MBP as a therapeu¬tic probe in patients with MS. In: J.F. Hallpike et al. (eds), Multiple sclerosis: Pathology, Diagnosis and Manegment. London, Chapman and Hell, 621 (1983)
94. Teitelbaum, D., Meshorer, A., Hirschfeld, T., Arnon, R., Selo, Μ.: Suppression of experimental allergic encepha¬lomyelitis by a synthetic polypeptide. Eur. J. immune( 1: 242 (1971)
95. Arnon, R.: EAE-susceptibility and suppression. immuπσl. Rev. 55:5 (1981)
96. Abramsky, O., Teitelbaum, D., Arnon, R.: Effect of COP-1 on patients with MS and acute disseminated encephalo¬myolitis – Preliminary report. J. Neurol. Sc~. 31: 433 ( 1977)
97. Bornstein, M.Β., Miller, Al., Teitelbaum, D., Arnon, R. and Sela, Μ.: MS-trial of a synthetic polypeptide. Ann. Neurol. 11: 317 (1982)
98. Bornstein, M.B., Miller, I.A., Slagle, S., Spada, V., Arnon, R., Sela, M. and Teitelbaum, D.: Clinical trials of a synthe¬tic polypeptide (copolymer 11 for the treatment of MS. In: R.E. Gonsette and P. Delmotte (eds), Immunological and Clinical Aspects of MS. Lancaster-Boston-The Hauge-Dordrecht. ΜΤΡ Press, 144 (1984)
99. Bornstein, Μ., Miller, A., Slagle, S.,-Weitzman, Μ., Cry¬stal, H., Drexler, E., Keilon, Μ., Merriam, A,, Wessertheil¬Smeller, S., Spada, V. et al.: A pilot trial of COP-1 in exa¬cerbating-remitting MS. N. Engl. J. Med 317:408(1987)
100. Weiner, H.L.: COP-1 therapy for MS. N. Engl. J. Med. 317.• 442 (1987)
101. Fauci, A.S., Dale, D.C. and Below, J.E.: Glucocorticoste¬roid therapy – mechanisms of action απd clinical conside¬rations. Ann. intern. Med. 84: 304 (1976)
102. Clarke, J.R., Gagnon, R.F., Gotch, F.M., Heyworth, Μ.F., McClennan, I.C.M., Truelove, S.C. and Waller, C.A.: The effect of prednisolone on leukocyte function in man. Clin. Exp. immunel. 28: 292 ‚1977)
103. Cooper, D.Α., Potts, V., Luckhurst, Ε. and Penny, R.: The effect of acute and prolonged administration of predniso¬lone and ACTH on lymphocyte subpopulations. Clin. Exp. immunel. 28: 467 (1977)
104. Lersson, Ε.L.: Cyclosporin A απd dexamethasone sup¬press Τ cell responses by selectively acting at distinct sites of the triggering process. J. immunol. 124.• 2828 (1960)
105. Miller, H.G., Newell, D.J. απd Ridley, A.: MS-treatment of acute exacerbations with ACTH. Lancet 2: 1120 (1961)
106. Rose, A.S., Kuzma, J.N., Kurtzke, J.F., Namerow, N.S., Sibley, W.A. and Tourtellotte, W.W.: Co-operative study in the evaluation of therapy in MS-ACTH vs placebo: final report. Neurology 20: 1 11970)
107. Perkin, G.D.: A critique of steroid trials in MS. Neuroepi¬demiology 6: 40 (1987)
108. Troiano, R., Hafsteii, M., Ruderman, M., Douling, P. and Cook, S.: Effect of high-dose intravenous steroid admini¬stration on contrast-enhancing computed tomographic scan lesions in MS. Ann. Neurol. 15: 257 (1984)
109. Tourtellotte, W.W., Baumhefner, R.W., Potvin, A.R., Ma, B.I., Potvin, J.H., Mendez, Μ. and Syndulko, K.: MS de novo CNS IgG synthesis – effects of ACTH and corticosleroids, Neurology 30: 1155 (1980)
110. Trotter, J.L and Garvey, W.F.: Prolonged effects of large dose methylprednisolone infusion in MS. Neurology 30: 702 (1980)
111.  Staiigaitis, S.M., Shapshak, P., Myers, L.W., Ellison, G.W.,.Tourtellotte, W.W., Lee, Μ.: Azathioprine απd ste¬roids are not more effective in decreasing MS intro blood¬brain-barrier IgG synthesis than steroids alone. Ann. Neurol. 18: 356 (1985)
112. Durelli, L., Cocito, D., Riecio, A., Barile, C., Bergamasco, B., Baggio, G.F., Rerla, F., Delsedime, M., Gusmazoli, G., Bergamini, L.: High-dose IV methylprednizolone in thetreatment of MS: clinical-immunologic correlations. Neu¬rology 36: 238 (1986)
113. 113. Milligan, N.M., Newcombe, R., Compstori, D.A.S.: A dou¬ble-blind controlled trial of high dose methylprednizolone in patients with ‘MS. 1. Clinical effects. J. Neural. Neuros urg. Psych. 50: 511 (1987)
114. Compston. D.A.S., Milligan, Ν.M., Hughes, Ρ.J., Gibbs, J., McBroom, V., Morgan, B.P., Campbell, A.K.: A double-blind controlled trial of high dose methylprednizolorie in patients with MS. J. Neural. Neurosurg. Psych. 50: 517 (1987)
115. Millar, J.H.D., Vas, C.J., Noronha, M.J., Liversedge, L.A., ‘Rawson, Μ.D.: Long-term treatment of MS with ACTH. Lancet 2: 429 (1967)
116. Kiessling, W.R.: Transdermal effects of a synthetic a¬melanotroρin/cόrticοtropin analog in MS. Arch. Neural.
     44: 995 (1987) ‘
117. Girard, P., Aimard, G., Pellet, H.: Thirapeutique immuno¬depressive en neurologie. Presse Mid. 75: 967 (1967)
118. Millac, P. and Miller, H.: Cyclophosphamide in MS. Lan¬cet 1: 783 (19691
119. Centrowski, W.: A preliminary trial of treatment of pa¬tients with MS with iv hydrocortisone hemisuccinate in combination with cyclophosphamide or cytosin arabino¬side. Neruol. Neurochir. Pal. 8.’ 47 (1974)
120. Gonsette, R.E., Demonty, L. Delmotte, P.: Intensive immunosuppression with cyclophosphamide in MS-fol¬low up of 110 patients for 2-6 years. J. Neural. 214: 173 (1977)
121. Hammes, O.R., Lamers, K.J.6., Reekers, P.: Effect of intensive immunosuppression an the course of chronic progressive MS. J. Neural. 233: 177 (1980)
122. Hauser, S.L., Dawson, D.M., Lehrich, J.R., Seal, M.F., Kevy, S.V., Propper, R.D., Mills, J.A., Weiner, H.L.: Inten¬sive immunosuppression in progressive MS – a randomized, three-arm study of high-dose iv cyclophosphamide, plasma exchange απd ACTH. N. Engl. J. Med. 308.• 173 11983}
123. Weiner, H.L., Hauser, S.L, Hafler, D.A., Fallis, R.J., Leh-rich, J.R., Dawson, D.M.: The use of cyclophosphamide in the treatment of MS. Ann. N.Y. Aced. Sc!. 436: 373 (1984)
124. Goodkin, D.E., Plencner, S., Palmer-Saxerud, J., Teetzen, Μ., Hertsgaard, D.: Cyclophosphamide in chronic pro¬gressive MS. Maintenance vs nonmaintenance therapy. Arch. Neural. 44: 823 (1987)
125. Myers, L.W., Fahey, J.L., Moody, D.J., Mickey, M.R., Frane, M.V., Ellison, G.N.: Cyclophosphamide “pulses” in chronic progressive MS. A preliminary clinical trial.Arch. Neural. 44: 828 (1987)
126. Aimerd, G., Confavreux, C., Ventre, J.J., Guillot, Μ., Devic, Μ.: Etude de 213 cos de sclerose eπ plaques trai¬te’s par I’azathioprine de 1967 i 1982. Rev. Neural, 139: 509 (1983)
127. Lhermitte, F., Marteau, R., Roullet, E., De Saxce, H., Lori-den, Μ.: Treitement prοlongέ de la sclerose en plaques
     par I’azathioprine doses moyennes-bilan de quinze
     aπnέes d’experience. Rev. Neural. 140: 553 (1984)
128. Sabouraud, C., Oger, J., Dercel, F., Madigand, Μ., Me¬rienne, Μ.: immunosuppression au long cours dons Ia sclerose eπ plaques: evaluation des traitements com¬mences avant 1972. Rev. Neural. 140: 125 (1984)
129. P.atzold, U. and Pocklington, P.: Azathioprine in MS – a 3 year controlled study of its effectiveness. J. Neural. 223: 97 (1980)
130. Shibasaki, H., McDonald, W.I., Kuroiwa, Y.: Racial modifi¬cation of clinical picture of MS – comparison between Ja¬panese and British patients. J. Neural Sc;. 49: 253 (1981)
131. Lhermitte, F., Marteau, R., Roullet, Ε.: Not so benign long term immunosuppression in MS? Lancet 1: 276 (1984)
132. Kinlen, L.J.: Immunosuppressive therapy and cancer. Cancer Surv. 1: 565 11982)
133. The British and Dutch MS Azathioprine Trial Group: Dou¬ble blind controlled trial of azalhioprine in the treatment of MS. J. Neural Neurosurg. Psych. 50: 1387 (1987)
134. Brendel, W., Seifert, J., Lob, G.: Effect of maximum immune suppression with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disor¬ders. Proc. R. Soc. Med. 65: 531 (1972)
135. Seland, T.P., McPherson, T.A., Grace, M., Lamoureux, G. Blain, J.G.: Evaluation of antithymocyte globulin in acute relapses of MS. Neurology 24: 34 (1974)
136. Mertin, J., Rudge, P., Kremer. Μ., Healy, M.J.R., Knight, S.C., Compston, A., Batchelor, J.R., Thompson, E.J., Hall-day, A.M., Denman, M., Medawar, P.Β.: Double-blind controlled trial of immunosuppression in the treatment of MS – final report. Lancet 2: 351 (1982)
137. Marteau, R., Lhermitte, F., De Saxce, H.: Anti lymphocyte serum in severe MS. Bλέπε βιpλ. υτ’ oριθμ. 78,49(1985)
138. Hafler, D.A., Fallis, R.J., Dawson, D.M„ Schlossman, S.F., Reinherz, E.L., Weiner, H.L.: Immunologic responses of progressive MS patients treated with an anti-T-cell monoclonal antibody, anti Ρ17. Neurology 36: 777 (1986)
139. Morris, P.J.: Cyclosporin A. Transplantation 32.• 349 (1981)
140. White, D.J.G. απd Caine, R.Y.: The use of cyclosporin Α. lmmunol. Rev. 65: 115 (1982)
141. Calder, V.L., Bellamy, A.S., Owen, S., Lewis, C., Rudge, P., Davison, A.N., Feldmann, Μ.: Effects of cyclosporin A on expression of lL-1 απd IL-2 receptors in normal and MS patients. Cl/n. Exp. lmmunol. 70: 570 (1987)
142. Bahia, M.Β., Antel, J.P., Reder, Α.Τ.; Nicholas, M.K., Ar¬nasorl, B.G.: Suppressor and cytolytic cell function in MS. Effect of cyclosporin A and IL-2. J. Gin. Invest. 78: 582 (1986)
143. Bolton, C., Allsopp, G., Cuzner, M.L.: The effect of cyclo¬sporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin. Exp. Immune!. 47.• 127 (1982)
144. Rumjanec, V.M., Smith, L.A., Morley, J.: Modulation by cyclosporin A of mononuclear cell distribution during EAE. (nt J. lmmuπopharmaεol. 6.’ 99 (1984)
145. Martin, J. and Smith, A.D.: Immune modulation by pro¬stagiandins and their precursors. !n: A.L. Willis et el. (eds). Handbook of Prostaglandins and Related Lipids. Boca iaton CRC Press, 1985
146. Rogers, T.J., Camp, L., Calhoun, K., Nowowiejski, I., Webb, D.R.: Suppression of Β cell and Τ cell responses by the T-cell-derived suppressor factors. Cell. immunol. 66: 269 (1982)
147. Rappaport, R.S. and Dodge, G.R.: Prostaglandin Ε inhibits the production of human IL-2. J. Esp. Med. 155.• 943 (1982)
148. Vervliet, G., Deckmyn. H., Carton, H., Billieu, A.: Influence of prostaglandin Εz and indomethacin on interferon-
     gamma production by cultured peripheral blood leukocy¬tes of MS patients and healthy donors. J. Clin. immune!. 5: 102 (1985)
149. Mathias, M.M. and Dupont, J.: The relationship of dietary fats to prostaglandin biosynthesis. Lipids 14:247(1979)
150. Bolton, C. and Cuzner, M.L.: Modification of EAE by non steroidal anti inflammatory drugs. In: A.N. Davison απd
     M.L. Cuzner (Eds). The suppression of EAE and MS. Academic Press, 189 (1980)
151. Thompson, R.H.S.: A biochemical approach to the pro¬blem of MS. Pro. R. Soc. Med. 59: 269 (1966)
152. Cherayil, G.D.: Sialic acid and fatty acid concentrations in lymphocytes, red blood cells, and plasma from patients with MS. J. Neurol. 5cl 63: 1 (1984)
153. Alter, M., Yamoor, M., Harshe, Μ.: MS and nutrition. Arch. Neurol 31: 267 (1974)
154. Nanji, A.Α. and Narod, S.: MS: latitude απd dietary fat: is pork the missing link? Med. Hypotheses 20: 279 (1986)
155. Miller, J.H.P., Zilkha, K.J., Langman, M.J.S.: Double blind trial of linoleic supplementation of the diet in MS. Br.
     Med. J. 1: 765 (1973)
156. Paty, D.W., Cousin, H.K., Reed,-S., Adlakha, Κ.: Linoleic acid in MS failure to show any therapeutic benefit. Acts
     Neurol. Scand 58: 53 (1978) .
157. Bates, D., Fawcett, P.R.W., Shaw, D.A., Weighiman, D.: Polyunsaturated fatty acids in the treatment of acute re¬mitting MS. Br. Med. J. 2: 1390 (1978)
158. Dworkin, R.H., Bates, D., Millar, J.H,D., Paty, D.W.: Liπο¬leic acid in MS. Neurology 34: 1441 (1984)
159. Bates, D.: bietary Therapy in MS. Bλ~ne βιβh. napαnoμnή un αριθμ. 78: 71 (1985)
160. Khatri, B.O., Koethe, S.M., McOuillen, M.P.: Plasmaphe¬resis with immunosuppressive drug therapy in progres¬sive MS – a pilot study. Arch. Neural. 41: 734 (1984)
161. Feria, S., Meneghetti, G., Sparta, S., Belloni, M., Ongeto, G.: Effect of lymphocytapheresis plus cyclophosphamide on the course of a chronic progressive form of MS. /tel. J. Neurol. Sc/. 6: 283 (1985)
162. Cook, S.D., Troisno, R., Zito, G., Lavenhar, Μ. Devereux,
     C., Hafstein, M., Hernandez, E., Vidaver, R., Dowling, P.: Effect of total lymphoic irradiation in chronic progressive MS. Lance! 1: 1405 (1986)
163. ΠoλuχρoνΙδης, I.: To υπeρβαρικό oξuγόνo στην ΘΕpαΠΕΓα της Σ.K.Π. (Ανoσκόnηση(. Sγχέφαλπς 24: 110 (1987)
164. Baxevanis, C.N., Reclos, G.J., Sfagos, C., Doufexis, Ε., Papageorgiou, C., Papamichail, Μ.: MS I. Monocyte sti-
     mulatory defect in mixed lymphocyte reaction associated
     with clinical disease activity. Clin. Exp. lmmun. 67: 362 (1987)
165. Reclos, G.J., Baxevanis, C.N., Sfagos, C., Papageorgiau, C., Tsokos, G.C., Papamichail, Μ.: MS II. Effects of pro¬thymosin a on the autologous and allogeneic ΜLR in patients with MS. Clin. Exp. lmmunol 70: 336 (1987)
166. Schulof, R.S. and Goldstein, A.L.: Clinical application of thymosin and other thymic hormones. In: R.A. Thomson and N.R. Rose (eds), Recent Advances in Clinical Immunology. Vol. 3, Churchill-Livingstone, 243 (1983)
167. Dabrwski, M.P., Dabrowska-Bernstein, Θ.K., Stasiak, A., Gajkowski, K., Korniluk, S.: immunologic and clinical evaluation of MS patients treated with cortocosteroids απd or calf thymic hormones. Ann. N.Y. Aced. Sc,. 496: 697 (1987)
168. Renoux, G. and Reroux, Μ.: Antigenic competition and non specific immunity after rickettsial infection in mice – Restoration of antibacterial immunity by phenyl-imido¬thiazole treatment. J. lmmunol 109: 761 (1972)
169. Gonsette. R.E., Delmotte, P., Decree, J., Decack, W., Verhaegen, H., Symoens, J.: Modulation of immunity in MS – a double-blind levamisol placebo controlled study in 85 patients. J. Neurol. 228: 65 (1982)
170. Mukhtrarova, A.A.• Comparative analysis of these of levamisole and pyrogenal in the treatment of MS. Zh Nevropatol. Psikhiatr. 85: 366 (1985)
171. Lawrence, H.S.: Transfer factor. Adv. lmmunol 11: 195 (1969)
172. Utermohlen, V., Winfield, J.B., Kulisek, E., Zabriskie, J.B.: Cell-mediated immunity to viral antigens in MS and other disorders. In: R.F. Beers and E.G. Bassett (eds). The Role of Immunological Factors in Infectious, Allergic and Autoimmune Processes. New York, Raven Press, 151 ( 1976)
173. Zabriskie, J.B., Espinoza, L.-R., Plank, C.R., Collins, R.C.: Cell mediated immunity to viral antigens in MS. Acta Neurol Scand. 55 Suppi. 63: 239 (1977)
174. Collins, R.C., Espinoza, L.R., Plank, C.R., Ebers, G.S., Rosenberg, A. απd Zabriskie, J.B.: A double blind trial of transfer factor vs placebo in MS patients. Chn. Exp. lmmunol. 33: 1 (1978)
175. Lamoureux, G., Gosgrove, J., Duquette, P., Lapierre, Y.,’ Jolicoeur, R., Vanderland, F.: A clinical and immunological study of the effects of transfer factor on MS pa¬tients. Clip. Exp. immunol. 43: 557 (1981)
176. easten, A., McLeod, J.G., Pollard, J.D., Walsh, J.C., Stewart, G.J., Garrick, R., Frith, J.A., Vom Der Brink, C.M.: Transfer factor in treatment of MS. Lancet 2: 931 ( 1980)
177. Van Haver et a1.: Transfer factor therapy in MS: a three-year prospective double-blind clinical trial. Neurology 36: 1399 (1986)
178. Keudewitz, P., Zander, H., Abb, J., Ziegler-Heitbrock, H.W., Riethmuller, G.: Genetic influence on natural cyto¬toxicity and interferon production in MS studies in mono-zygotic discordant twins. Hum. lmmunol 7: 51 (1983)
179. Tovell, D.R., McRobbie, J.A., Warren, K.G., Tyrrell, D.L.: Interferon production by lymphocytes from MS and non-MS patients. Neurology 33: 640 (1983)
180. Hammann, K.P., Hopf, H.C.: Determination of interferon-gamma in the peripheral blood of MS patients in remission, using a chemiluminescence technique. J. New’o¬immune!. 13.• 9 (1986)
181. Fog, T.: Interferon treatment of MS patients. Α pilot study. In: A. Βοese (ed.), Search for the Cause of MS and other Chronic Diseases of the CNS. Verlag, Chemie, 490(1 980)
182. Jacobs, L., O’Malley, J., Freeman, Α., Ekes, R.: Intrathecal interferon reduces exacerbations of MS. Science 214.’ 1026 (1981)
183. Jacobs, L, Ο’Μalley, J., Freeman, Α., Ekes, R., Reese, P.A.: Intrathecal interferon in the treatment of MS. Pa¬tient follow-up. Arch. NeuroL 42: 841 (1985)
184. Jacobs, L., Salazar, A.M., Herndon, R., Reese, P.A., Freeman, A., Josefowicz, R.. Cuetter, A., Husain, F., Smith, W.Α., Ekes, R. et al,: Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of MS. Lancet 2: 1411 {1986)
185. Jacobs, L, Salazar, A.M., Herndon, R., Reese, P.A., Freeman, A., Josefowicz, R. at al.: Intrathecally admini¬stered natural human fibroblast interferon reduces exa¬cerbations of MS. Results of a muclicenter, double-blind study. Arch. Neurol. 44.’ 589 (1987)
186. Knobler, R.L. Paiiitch, H.S., Braheny, S.L., Sipe, L.C., Rice, G.P.A., et al.: Systemic alpha-interferon therapy of MS. Neurology 34.• 1273 (1984)
187. Panitch, H.S.: Systemic alpha-interferon in MS. Long term patient follow-up. Arch. Neurol. 44: 61 (1987)
188. ΜcFarlin, D.E., Bever, C.T., Salazar, A.M., Levy, H.B.: Α preliminary trial of poly (I. C)-LC in MS. J. Biol. Response Med. 4: 544 (1985)
189. Bever, C.T., Salazar, A.Μ., Keeley, E., Ferraccio, B.E., Rose, J.W., McFarland, H.F., Levy, H.B., McFarlin, D.E.: Preliminary trial of poly ICLC in chronic progressive MS. Neurology 36.• 494 (1986)
190. Camenga, D.L., Johnson, K.P., Alter, M. et al.: Systemic recombinant alpha-2-interferon therapy in relapsin MS. Arch. Neurol. 43: 1239 (1986)
191. Panitch, H.S., Hirsch, R.L. Schindler, J., Johnson, K.P.: Treatment of MS with gamma interferon: exacerbations associated with activation of the immune system. Neuro
192. logy 37: 1097 (1987)
193. Ruutiainen, .J., Panelius, M., Cantell, K.: Toxic effects of interferon administered intrathecelly. Br. Med. J. Clin. Res, 286: 940 (1983)
194. Rohatiner, A.Z.S., Prior, P.F. Burton, A.C., Smith, A.T., Balkwill, F.R., Lister, Τ.A.; CNS toxicity of interferon, Br. J. Cancer 47: 419 (1983)
195. Habif, D.V., Lipton, R., Cantell, Κ.: Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. &ρ. Biο!. Med. 149.’ 287 (1975)